source
- REVELUTION-2 trial assesses cardiovascular safety of relugolix plus abiraterone in high‑risk prostate cancerThe REVELUTION-2 study is focused on measuring the heart‑related risks associated with a hormone‑therapy regimen that combines relugolix and abiraterone acetate in patients with high‑risk prostate…
- Second Clinical Scenario - Progressive Disease Despite Hematocrit ControlPolycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.onclive · 3mo ago↗ source
- Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery